Stocks · Healthcare · Biotechnology
Vertex Pharmaceuticals Incorporated VRTX
$504.73 -0.40% Close, Oct 2, 2026 · NASDAQ · Market cap $128.10B
High qualityLow risk
Next earnings report: Nov 2, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- The stock is in an uptrend: above its 200-day average for 79 trading days, with the 50-day average above the 200-day.
- The shares trade at 29.4× trailing earnings, higher than 82% of the company's own readings over the past five years.
- Diluted EPS over the last four quarters was $17.18, up 22.8% year over year.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 46%
- EPS growth (TTM, YoY)Top 39%
- FCF growth (TTM, YoY)Bottom 50%
- Revenue growth, 3-year CAGRTop 49%
- Revenue growth accelerationTop 43%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 7%
- Gross marginTop 23%
- Operating marginTop 4%
- Cash conversion (OCF / net income)Bottom 22%
- Accruals (lower is better)Bottom 16%
- Net debt / EBITDA (lower is better)Top 22%
- Interest coverTop 1%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 16%
- Free-cash-flow yieldTop 26%
- EBITDA / enterprise valueTop 25%
- Sales / enterprise valueBottom 31%
- P/E vs own 5-year history (lower is better)Bottom 16%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 39%
- 6-month returnTop 43%
- 1-year return vs S&P 500Top 40%
- Distance from 52-week highTop 15%
- Trend checklist (0–4)Top 39%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 47%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyTop 34%
- Upside to consensus price targetBottom 22%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 5%
- Maximum drawdown, 3 yearsTop 5%
- Beta vs S&P 500 (lower is better)Top 14%
- Net debt / EBITDA (lower is better)Top 22%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 10.4% | 10.6% | ↑ |
| Gross margin | 86.1% | 86.0% | ↓ |
| Operating margin | 34.4% | 38.6% | ↑ |
| FCF margin | 30.6% | 30.1% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 10.6% | 10.4% | ↑ | Top 46% |
| EPS growth (TTM, YoY) | 22.8% | — | Top 39% | |
| Gross margin | 86.0% | 86.1% | ↓ | Top 23% |
| Operating margin | 38.6% | 34.4% | ↑ | Top 4% |
| Net margin | 34.9% | 31.9% | ↑ | — |
| Free-cash-flow margin | 30.1% | 30.6% | ↓ | — |
| Return on invested capital | 17.3% | — | Top 7% | |
| Revenue growth, 3-year CAGR | 10.6% | — | Top 49% |
Quality of earnings and balance sheet
- Cash conversion (OCF / net income)Above 1× means profits are backed by cash.
- 0.97×
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- 0.4%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 5.5%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +2.2 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- -0.77×
- Interest cover (operating income / interest)How many times operating profit covers interest.
- 738.2×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- 1.64%
- Shareholder yield
- 1.64%
- Share count change, 1 year
- -1.2%
- Share count change, 3-year CAGR
- -0.6%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 4, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 4 of 8
- Average EPS surprise, last 4
- +2.2%
- Average 2-day reaction, last 8
- +0.4%
- Positive 20 days after report
- 5 of 8
Analysts
- Consensus price target
- $573.07
- Target vs current price
- +13.5%
- Analysts with a rating
- 56
- Share rating Buy or Strong Buy
- 86%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 3, 2026 | -0.2% | -1.3% | +4.0% | +13.5% | — |
| May 4, 2026 | +5.4% | +1.4% | +1.4% | +3.4% | +14.0% |
| Feb 12, 2026 | -1.6% | +0.8% | +1.7% | +3.7% | -6.8% |
| Nov 3, 2025 | +5.0% | +0.1% | -3.8% | +0.0% | +11.8% |
| Aug 4, 2025 | +5.4% | +2.2% | -20.7% | -15.4% | -9.1% |
| May 5, 2025 | -4.5% | -0.2% | -15.2% | -11.1% | -6.4% |
| Feb 10, 2025 | -1.0% | +0.1% | -2.2% | +6.5% | -4.1% |
| Nov 4, 2024 | +5.8% | +0.4% | +9.7% | -1.1% | -2.0% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 3, 2026 | $4.73 | $4.74 | -0.2% | $3.33B |
| May 4, 2026 | $4.47 | $4.24 | +5.4% | $2.99B |
| Feb 12, 2026 | $5.03 | $5.11 | -1.6% | $3.19B |
| Nov 3, 2025 | $4.80 | $4.57 | +5.0% | $3.08B |
| Aug 4, 2025 | $4.52 | $4.29 | +5.4% | $2.96B |
| May 5, 2025 | $4.06 | $4.25 | -4.5% | $2.77B |
| Feb 10, 2025 | $3.98 | $4.02 | -1.0% | $2.91B |
| Nov 4, 2024 | $4.38 | $4.14 | +5.8% | $2.77B |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| P/E (trailing) | 29.4× | 26.8× | 82th | Top 16% |
| P/E (forward) | 27.0× | — | — | — |
| EV / EBITDA | 22.8× | — | — | Top 25% |
| EV / Sales | 9.82× | — | — | Bottom 31% |
| Free-cash-flow yield | 2.96% | — | — | Top 26% |
| Earnings yield | 3.40% | — | — | Top 16% |
P/E over the past five years
Range 22.7× – 32.1× since Jun 30, 2021. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
What moved the stock over the past year
- Price return, 1 year
- +24.9%
- Earnings per share growth (TTM)
- +22.8%
- Change in P/E multiple
- +4.0%
Most of the move came from earnings growth.
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 79
- 50-day average slope (20 days)
- +2.1%
- 200-day average slope (20 days)
- +1.7%
- Distance from 50-day average
- -2.6%
- Distance from 200-day average
- +6.6%
- RSI (14)
- 39.0
- Relative volume
- 0.94×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 25.8%
- Volatility vs own 5-year history
- 45th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.46
- Correlation with S&P 500
- 0.21
- Current drawdown from 1-year high
- -9.5%
- Maximum drawdown, 3 years
- -29.1%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Oct 13, 2020 | Oct 5, 2021 | -35.9% | 246 days | 129 days (Apr 8, 2022) |
| Nov 8, 2024 | Aug 8, 2025 | -29.1% | 185 days | 225 days (Jul 2, 2026) |
| Apr 13, 2022 | May 11, 2022 | -19.2% | 19 days | 30 days (Jun 24, 2022) |
| Jan 30, 2024 | Apr 30, 2024 | -11.9% | 63 days | 16 days (May 22, 2024) |
| Nov 22, 2022 | Jan 9, 2023 | -11.9% | 31 days | 15 days (Jan 31, 2023) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $128.10B
- P/E (TTM)
- 29.4
- EPS, diluted (TTM)
- $17.18
- Revenue (TTM)
- $12.62B
- 52-week range
- $400.74 – $560.25
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $7.57B | $8.93B | $9.87B | $11.02B | $12.07B |
| Gross profit | $6.67B | $7.85B | $8.61B | $9.49B | $10.27B |
| Operating income | $2.78B | $4.31B | $3.83B | -$232.9M | $4.76B |
| Net income | $2.34B | $3.32B | $3.62B | -$535.6M | $3.95B |
| EPS (diluted) | $9.01 | $12.82 | $13.89 | -$2.08 | $15.32 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.77B | $2.91B | $2.77B | $2.96B | $3.08B | $3.23B | $2.99B | $3.33B |
| Net income | $1.05B | $913.0M | $646.3M | $1.03B | $1.08B | $1.19B | $1.03B | $1.10B |
| EPS (diluted) | $4.01 | $3.50 | $2.49 | $3.99 | $4.20 | $4.65 | $4.02 | $4.31 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | $2.64B | $4.13B | $3.54B | -$492.6M | $3.63B |
| Capital expenditure | -$235.0M | -$204.7M | -$258.4M | -$297.7M | -$437.6M |
| Free cash flow | $2.41B | $3.93B | $3.28B | -$790.3M | $3.19B |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | -$1.32B | $14.3M | -$293.0M | -$1.06B | -$1.89B |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $7.85B
- Total assets
- $27.42B
- Total liabilities
- $7.18B
- Total debt
- $1.98B
- Net debt
- -$4.17B
- Shareholders’ equity
- $20.25B
As of Jun 30, 2026 (filed Aug 4, 2026).
Short interest
- Shares sold short
- 4,716,867
- Days to cover
- 5.03
- Change vs previous report
- +1.2%
FINRA short interest, settlement date Sep 15, 2026.
Stock splits
- Aug 24, 2000
- 2-for-1